TKM-Ebola was an experimental antiviral drug for Ebola disease that was developed by Arbutus Biopharma (formerly Tekmira Pharmaceuticals Corp.) in Vancouver, Canada. The drug candidate was formerly known as Ebola-SNALP. TKM-Ebola is a combination of small interfering RNAs targeting three of the seven proteins in Ebola virus: Zaire Ebola L polymerase, Zaire Ebola membrane-associated protein (VP24), and Zaire Ebola polymerase complex protein (VP35).
TKM-Ebola was an experimental antiviral drug for Ebola disease that was developed by Arbutus Biopharma (formerly Tekmira Pharmaceuticals Corp.) in Vancouver, Canada. The drug candidate was formerly known as Ebola-SNALP. TKM-Ebola is a combination of small interfering RNAs targeting three of the seven proteins in Ebola virus: Zaire Ebola L polymerase, Zaire Ebola membrane-associated protein (VP24), and Zaire Ebola polymerase complex protein (VP35).
Source: Wikipedia "TKM-Ebola" · CC BY-SA 4.0
Share this article: X · Bluesky